在伊朗治疗中度至重度活性的性结肠炎的静脉和皮下vedolizumab:基于模型的成本效益评估
Kimia Niksalehi1,2, Anita Oyarhossein2, Soroush Fariman3
1Pharmaceutical Strategic Analysis and Research, PASAR, Tehran, Iran.
概括
静脉注射或皮下注射的维多利祖马布比伊朗中度至重度性结肠炎 (UC) 治疗的因弗力西马布更具成本效益. 这种疗法提供了降低成本和改善质量调整寿命年 (QALYs).
科学领域:
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,需要有效和经济高效的治疗策略.
- 目前对中度至重度UC的治疗选择包括生物药物,如infliximab和vedolizumab.
- 评估不同治疗方法的成本效益对于医疗保健资源分配至关重要.
研究的目的:
- 评估静脉注射 (IV) 和皮下注射 (SC) 韦多利祖马布的成本效益与伊朗中度至重度UC的因弗力西马布相比.
- 提供证据,证明韦多利祖马布被列入伊朗国家健康表格.
主要方法:
- 使用了结合决策树和马尔科夫模型的决策分析模型.
- 直接和间接成本是从伊朗社会角度计算的.
- 用质量调整的寿命年 (QALYs) 来衡量有效性,数据来源于已发表的文献. 为了评估不确定性,进行了敏感性分析.
主要成果:
- 与infliximab相比,vedolizumab (IV和SC) 的成本较低,QALY也较高.
- 维多利祖马布的增量成本效益比率 (ICER) 是负的,表明成本效益.
- 敏感性分析证实了在各种场景中,维多利祖马布的有利成本效益.
结论:
- 维多利祖马布 (IV和SC) 是伊朗中度至重度UC的经济有效的治疗策略.
- 该研究建议将维多利祖马布纳入伊朗国家配方.
- 成本效益受药物价格和患者对维护疗法的反应率的影响.
更多相关视频
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
101
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
101
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
84
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
84
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
98
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
98
01:29Inflammatory Bowel Disease IV: Pharmacological Management
79
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
79
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
01:17Drugs for Treatment of Diarrhea-Predominant IBS
117
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
117